BBAG.F Stock Overview
BB Biotech AG is an equity fund launched and managed by Bellevue Asset Management AG.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 3/6 |
BB Biotech AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CHF47.23 |
| 52 Week High | CHF57.70 |
| 52 Week Low | CHF43.65 |
| Beta | 0.83 |
| 1 Month Change | -16.79% |
| 3 Month Change | -18.15% |
| 1 Year Change | -14.13% |
| 3 Year Change | -46.84% |
| 5 Year Change | -34.22% |
| Change since IPO | -82.43% |
Recent News & Updates
Recent updates
Shareholder Returns
| BBAG.F | US Capital Markets | US Market | |
|---|---|---|---|
| 7D | 0% | -2.6% | -3.7% |
| 1Y | -14.1% | 22.7% | 20.5% |
Return vs Industry: BBAG.F underperformed the US Capital Markets industry which returned 22.2% over the past year.
Return vs Market: BBAG.F underperformed the US Market which returned 20.2% over the past year.
Price Volatility
| BBAG.F volatility | |
|---|---|
| BBAG.F Average Weekly Movement | n/a |
| Capital Markets Industry Average Movement | 3.4% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: BBAG.F has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine BBAG.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1993 | 10 | n/a | www.bbbiotech.ch/en/bb-biotech/ |
BB Biotech AG is an equity fund launched and managed by Bellevue Asset Management AG. The fund invests in the public equity markets across the globe. It primarily invests in stocks of companies that are engaged in medications and diagnostics based on modern biotechnology.
BB Biotech AG Fundamentals Summary
| BBAG.F fundamental statistics | |
|---|---|
| Market cap | US$2.51b |
| Earnings (TTM) | -US$226.67m |
| Revenue (TTM) | US$38.40k |
Over9,999x
P/S Ratio-11.2x
P/E RatioIs BBAG.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BBAG.F income statement (TTM) | |
|---|---|
| Revenue | CHF35.00k |
| Cost of Revenue | CHF0 |
| Gross Profit | CHF35.00k |
| Other Expenses | CHF206.64m |
| Earnings | -CHF206.61m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Apr 26, 2024
| Earnings per share (EPS) | -3.77 |
| Gross Margin | 100.00% |
| Net Profit Margin | -590,305.71% |
| Debt/Equity Ratio | 13.1% |
How did BBAG.F perform over the long term?
See historical performance and comparison